Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01107522 | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | unknown | Phase 1 | 100 | Tactical Therapeutics, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06462716 | A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Apr 13, 2025 |
| clinicaltrials |
| NCT05650242 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors | unknown | Phase 1 | 177 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06410703 | CAN1012 Combined With PD-1 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Canwell Biotech LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04740398 | A Study of CBP-1008 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 143 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04928612 | A Study of CBP-1018 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 170 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06404281 | γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors | unknown | Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06553846 | A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05244551 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 85 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Aug 12, 2024 | clinicaltrials |
| NCT05266612 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 12 | Virogin Biotech Canada LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04282031 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | unknown | Phase 1 / Phase 2 | 224 | Beta Pharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05076552 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | unknown | Phase 1 | 30 | Tachyon Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06199908 | AMT-562 in Patients With Selected Advanced Solid Tumors | unknown | Phase 1 | 72 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05731752 | Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05620862 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | unknown | Phase 1 | 68 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05880043 | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 50 | GI Cell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06329206 | A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 156 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06439589 | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 88 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05830045 | A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 180 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06473948 | To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects | unknown | Phase 1 | 27 | JemincareINDUSTRY | 0 | Jun 25, 2024 | clinicaltrials |
| NCT05819684 | A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 133 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06466265 | Study of DNP002 in Patients With Solid Tumors | unknown | Phase 1 | 36 | Kumho HT Inc.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06233292 | A Study of ZG005 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 484 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06239298 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 130 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06094777 | A Study of HY-0102 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06433726 | A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05564858 | A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors | unknown | Phase 1 | 107 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT05650580 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors | unknown | Phase 1 | 26 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05751356 | TR128 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06394622 | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | unknown | Phase 1 | 12 | Fudan UniversityOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05804526 | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 82 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05865925 | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 78 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06368960 | BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors(BM201-1001) | unknown | Phase 1 | 36 | InnoBM Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06348290 | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | unknown | Phase 1 | 72 | JemincareINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT06247657 | A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06139536 | Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients | unknown | Phase 1 | 210 | Bio-Thera SolutionsINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05103046 | First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 68 | 1200 Pharma, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05877664 | Study of ZG0895.HCl in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 110 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06205082 | A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor | unknown | Phase 1 | 81 | LittDD Medicines LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 9, 2025source: clinicaltrials